Vaccine against the mosquito-borne viral disease will be accessible to the world very soon, says none other than the pharma major Sanofi. He has announced that the world’s first vaccine against dengue may be available by the second half of 2015.
Dengue affects lakhs of people annually, has been a serious challenge to public health in India. As per the reports, this vaccine will provide a 95.5% protection against severe dengue and an 80.3% reduction in the risk of hospitalization.
The French drugmaker’s vaccine unit, Sanofi Pasteur says that they will file for registration of its vaccine candidate and subject to regulatory approval the world’s first dengue vaccine could be available by the second half of 2015
The company said in a statement that the results of the last stage of the clinical study showed that the vaccine gives a 95.5 per cent protection against severe dengue and an 80.3 per cent reduction in the risk of hospitalization.
Its phase III efficacy clinical study program for the dengue vaccine candidate was conducted in over 31,000 participants across 10 endemic countries in Asia and Latin America, the company added.
Olivier Charmeil, Sanofi Pasteur president and CEO said, “We plan to submit the vaccine for licences in 2015 in endemic countries where dengue is a public health priority.”
Dengue is a serious health concern in India, causing a significant but under-reported burden, said Sanofi Pasteur India head Stephan Barth.
He said, “Over recent months we have seen a worrying increase in cases in many parts of the country, putting a huge strain on healthcare systems. India is part of Sanofi Pasteur’s global deveopment strategy for dengue vaccine".
Committed to dengue vaccine research for more than 20 years, Sanofi Pasteur aims to make the tropical ailment the next vaccine-preventable disease, Mr. Barth added.